(119) Evaluation of Trilaciclib Use and Chemotherapy Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

Poster Abstract:

Background: Chemotherapy-induced myelosuppression (CIM) is a common dose-limiting and potentially fatal toxicity of chemotherapy, characterized by reduced production of red blood cells, white blood cells, and/or platelets, leading to anemia, neutropenia, and thrombocytopenia. This substantial burden leads to suboptimal health outcomes and increased healthcare utilization. Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor and is the first and only myeloprotection therapy approved to decrease CIM among adults with extensive-stage small cell lung cancer when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen. Studies elucidating the real-world outcomes of trilaciclib have been limited since its approval in 2021.

Objective: The objective of this study is to evaluate chemotherapy-induced myelosuppression outcomes of patients with extensive-stage small cell lung cancer who received platinum/etoposide-containing or topotecan-containing chemotherapy with or without trilaciclib.

Method: This was a single-center retrospective study of patients with extensive-stage small cell lung cancer who received chemotherapy with or without trilaciclib from 2018 to October 31, 2023, at Zuckerberg Cancer Center. The inclusion criteria for analysis included: adults 18 years and older, histologically confirmed extensive-stage small cell lung cancer, and administration of platinum/etoposide-containing or topotecan-containing chemotherapy with or without trilaciclib. Outcomes included myelosuppression events and grade (anemia, neutropenia, thrombocytopenia), supportive care utilization (granulocyte-colony stimulating factor and RBC and/or platelet transfusion), and fever > 38.5°C. Information on progression of disease and death was also collected.

Results: Results pending.

Discussion/

Conclusion: Discussion/conclusion pending.

References (must also be included in final poster): 1. Maxwell MB, Maher KE. Chemotherapy-induced myelosuppression. Semin Oncol Nurs. 1992;8(2):113-123. doi:10.1016/0749-2081(92)90027-z
2. Epstein RS, Weerasinghe RK, Parrish AS, Krenitsky J, Sanborn RE, Salimi T. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers. J Med Econ. 2022;25(1):108-118. doi:10.1080/13696998.2021.2020570
3. Dhillon S. Trilaciclib: First Approval. Drugs. 2021;81(7):867-874. doi:10.1007/s40265-021-01508-y